• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估减少表柔比星载入药物洗脱微球M1(DC Bead M1™)所需加载时间的最便捷有效方法。

An Evaluation of the Most Convenient and Effective Procedure for Reducing the Loading Time of Epirubicin Into the Drug-Eluting Bead M1 (DC Bead M1™).

作者信息

Kawamura Yusuke, Akuta Norio, Yamamoto Shigeki, Eriksson Yasuka, Hosaka Tetsuya, Saitoh Satoshi, Sezaki Hitomi, Suzuki Fumitaka, Ikeda Kenji, Kumada Hiromitsu

机构信息

Hepatology, Toranomon Hospital, Tokyo, JPN.

Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, JPN.

出版信息

Cureus. 2024 Oct 25;16(10):e72352. doi: 10.7759/cureus.72352. eCollection 2024 Oct.

DOI:10.7759/cureus.72352
PMID:39588457
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11586879/
Abstract

Background and objective Drug-eluting beads (DEB) have been highly useful in the current treatment strategies for multiple and large hepatocellular carcinomas (HCC) with or without systemic therapy. Recently, smaller beads have become available in Japan. In this study, we aimed to evaluate the most convenient and effective way to reduce the loading time of epirubicin into the drug-eluting beads M1 (DC Bead M1; 70-150 µm). Methods To reduce the loading time of epirubicin into DC Bead M1, we used a method that involved mixing the drug and then agitating the solution using vortexing: Group A: agitated for 15 sec; Group B: agitated for 20 sec; Group C: agitated for 30 sec; and Group D: left at room temperature as the control group. After the loading of epirubicin by each method, the supernatant concentration of epirubicin was assayed at 5, 10, 15, 20, 30, 60, and 120 min. Results Epirubicin loading rates for DC Bead M1 at five min were 99.7% in Group A, 98.7% in Group B, 99.6% in Group C, and 99.5% in Group D. The four groups reached an equilibrium between five and 120 min. Surprisingly, Group D (left at room temperature for five min) showed the same level of epirubicin loading rate compared to that of Groups A, B, and C at five min (=0.566). Morphological analysis showed that there were no significant morphological changes for each agitated time up to 30 sec compared with that observed for the beads left at room temperature. Conclusions The most convenient and effective way for reducing the loading time of epirubicin into DC Bead M1 was observed in Group D (left at room temperature for five min).

摘要

背景与目的 药物洗脱微球(DEB)在目前伴有或不伴有全身治疗的多发性和大型肝细胞癌(HCC)治疗策略中具有很高的应用价值。最近,更小的微球已在日本上市。在本研究中,我们旨在评估将表柔比星载入药物洗脱微球M1(DC Bead M1;70 - 150 µm)的最便捷有效的方法。方法 为减少表柔比星载入DC Bead M1的时间,我们采用了一种先混合药物然后通过涡旋搅拌溶液的方法:A组:搅拌15秒;B组:搅拌20秒;C组:搅拌30秒;D组:室温放置作为对照组。通过每种方法载入表柔比星后,在5、10、15、20、30、60和120分钟时测定表柔比星的上清液浓度。结果 5分钟时,DC Bead M1的表柔比星载入率在A组为99.7%,B组为98.7%,C组为99.6%,D组为99.5%。四组在5至120分钟之间达到平衡。令人惊讶的是,D组(室温放置5分钟)在5分钟时的表柔比星载入率与A、B、C组相同(=0.566)。形态学分析表明,与室温放置的微球相比,搅拌时间长达30秒时,各搅拌时间下均未观察到明显的形态学变化。结论 在D组(室温放置5分钟)中观察到了将表柔比星载入DC Bead M1的最便捷有效的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e441/11586879/5cf22cc1d672/cureus-0016-00000072352-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e441/11586879/c886d8aff281/cureus-0016-00000072352-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e441/11586879/4fe8e5d44ad8/cureus-0016-00000072352-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e441/11586879/5cf22cc1d672/cureus-0016-00000072352-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e441/11586879/c886d8aff281/cureus-0016-00000072352-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e441/11586879/4fe8e5d44ad8/cureus-0016-00000072352-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e441/11586879/5cf22cc1d672/cureus-0016-00000072352-i03.jpg

相似文献

1
An Evaluation of the Most Convenient and Effective Procedure for Reducing the Loading Time of Epirubicin Into the Drug-Eluting Bead M1 (DC Bead M1™).评估减少表柔比星载入药物洗脱微球M1(DC Bead M1™)所需加载时间的最便捷有效方法。
Cureus. 2024 Oct 25;16(10):e72352. doi: 10.7759/cureus.72352. eCollection 2024 Oct.
2
Loading, release and stability of epirubicin-loaded drug-eluting beads.表柔比星载药洗脱微球的负载、释放及稳定性
J Oncol Pharm Pract. 2016 Aug;22(4):591-8. doi: 10.1177/1078155215594416. Epub 2015 Jul 8.
3
Clinical Impact and Significant Technical Points of Transarterial Chemoembolization (TACE) Using the Smaller Drug-Eluting Bead M1 (DC Bead M1™) for Hepatocellular Carcinoma: A Case Series.使用较小尺寸载药微球M1(DC Bead M1™)经动脉化疗栓塞术(TACE)治疗肝细胞癌的临床影响及重要技术要点:病例系列
Cureus. 2024 Nov 25;16(11):e74415. doi: 10.7759/cureus.74415. eCollection 2024 Nov.
4
Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media.载表柔比星DC微球™与不同非离子型造影剂的相容性。
J Oncol Pharm Pract. 2016 Dec;22(6):749-756. doi: 10.1177/1078155215607088. Epub 2015 Oct 1.
5
Stability of irinotecan-loaded drug eluting beads (DC Bead) used for transarterial chemoembolization.用于经动脉化疗栓塞的载伊立替康药物洗脱微球(DC微球)的稳定性
J Oncol Pharm Pract. 2010 Mar;16(1):53-61. doi: 10.1177/1078155209337650. Epub 2009 Jul 17.
6
An Attempt to Shorten Loading Time of Epirubicin into DC Beads Using Vibration and a Sieve.利用振动和筛网缩短表柔比星载入DC微球时间的尝试
Cardiovasc Intervent Radiol. 2017 Apr;40(4):585-590. doi: 10.1007/s00270-016-1354-x. Epub 2017 Feb 21.
7
Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.比较载药微球 DC 珠-伊立替康和 DC 珠-拓扑替康在局部递药治疗胰腺癌中的应用。
J Mater Sci Mater Med. 2010 Sep;21(9):2683-90. doi: 10.1007/s10856-010-4107-4. Epub 2010 Jun 19.
8
Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma.经肝动脉化疗栓塞术联合表柔比星洗脱微球与肝移植前经肝动脉栓塞术治疗肝细胞癌的比较。
J Vasc Interv Radiol. 2010 Mar;21(3):327-32. doi: 10.1016/j.jvir.2009.10.038. Epub 2010 Jan 22.
9
Transcatheter embolization of hepatocellular carcinoma with epirubicin-loaded DC beads in Chinese patients.载表柔比星DC微球经导管肝动脉栓塞术治疗中国肝细胞癌患者
Transl Cancer Res. 2019 Feb;8(1):279-289. doi: 10.21037/tcr.2019.01.36.
10
Efficacy and safety of raltitrexed-eluting CalliSpheres bead transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma: a single-arm, prospective study.雷替曲塞洗脱载药微球经动脉化疗栓塞术治疗中期肝细胞癌患者的疗效与安全性:一项单臂前瞻性研究
Ther Adv Med Oncol. 2024 Feb 14;16:17588359241229661. doi: 10.1177/17588359241229661. eCollection 2024.

引用本文的文献

1
Clinical Impact and Significant Technical Points of Transarterial Chemoembolization (TACE) Using the Smaller Drug-Eluting Bead M1 (DC Bead M1™) for Hepatocellular Carcinoma: A Case Series.使用较小尺寸载药微球M1(DC Bead M1™)经动脉化疗栓塞术(TACE)治疗肝细胞癌的临床影响及重要技术要点:病例系列
Cureus. 2024 Nov 25;16(11):e74415. doi: 10.7759/cureus.74415. eCollection 2024 Nov.